- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Longeveron to Present at Biotech Showcase 2025 | 1 | GlobeNewswire (USA) | ||
| 13.11. | Longeveron reports Q3 results | 2 | Seeking Alpha | ||
| 12.11. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.11. | A Look Ahead: Longeveron's Earnings Forecast | 5 | Benzinga.com | ||
| 11.11. | Longeveron ernennt Devin Blass zum neuen CTO | 2 | Investing.com Deutsch | ||
| 11.11. | Longeveron names Devin Blass as new CTO | 1 | Investing.com | ||
| 11.11. | Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) | 2 | GlobeNewswire (USA) | ||
| 04.11. | Peeling Back The Layers: Exploring Longeveron Through Analyst Insights | 1 | Benzinga.com | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 27.10. | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 85 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 09.10. | Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 07.10. | Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day | 4 | GlobeNewswire (USA) | ||
| 02.10. | Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 1 | GlobeNewswire (USA) | ||
| 26.09. | BioMedNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa | 1 | iNVEZZ.com | ||
| 26.09. | Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa | 2 | GlobeNewswire (USA) | ||
| 26.08. | Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 15.08. | Longeveron reports Q2 results | 5 | Seeking Alpha | ||
| 15.08. | Earnings call: Longeveron reports progress on Lomecel-B, eyes FDA talks | 2 | Investing.com | ||
| 06.08. | Longeveron Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.07. | Longeveron surges 14% on phase 2 Lomecel-B Alzheimer's data | 3 | Seeking Alpha | ||
| 29.07. | Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates | 2 | InvestorPlace |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| CYTODYN | 0,129 | +16,22 % | CytoDyn Inc.: December 2024 Letter to Shareholders | VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc. ("CytoDyn" or the "Company") achieved multiple crucial milestones... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| SOL GLOBAL INVESTMENTS | 0,242 | +1,68 % | Eine 1.100%-Krypto-Aktie, die MicroStrategy alt aussehen lässt… | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ANAVEX LIFE SCIENCES | 8,532 | +3,04 % | Anavex Life Sciences, Limoneira set to report earnings Monday | ||
| CERUS | 1,548 | +1,84 % | Cerus Corporation Announces Third Quarter 2024 Financial Results | CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024.
Total revenue for the three... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,330 | +1,54 % | WINT stock touches 52-week low at $0.32 amid steep annual decline |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,44 % bei einem Aktienkurs von 1,655 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.
